vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and WORKIVA INC (WK). Click either name above to swap in a different company.
WORKIVA INC is the larger business by last-quarter revenue ($238.9M vs $207.8M, roughly 1.1× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 4.9%, a 52.4% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $50.7M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Workiva, Inc. is a global software-as-a-service (SaaS) company. It provides a cloud-based connected and reporting compliance platform that enables the use of connected data and automation of reporting across finance, accounting, risk, and compliance.
IDYA vs WK — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $238.9M |
| Net Profit | $119.2M | $11.8M |
| Gross Margin | — | 80.7% |
| Operating Margin | 52.2% | 3.3% |
| Net Margin | 57.4% | 4.9% |
| Revenue YoY | — | 19.5% |
| Net Profit YoY | 330.1% | 234.0% |
| EPS (diluted) | $1.33 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $238.9M | ||
| Q3 25 | $207.8M | $224.2M | ||
| Q2 25 | — | $215.2M | ||
| Q1 25 | — | $206.3M | ||
| Q4 24 | — | $199.9M | ||
| Q3 24 | $0 | $185.6M | ||
| Q2 24 | $0 | $177.5M | ||
| Q1 24 | $0 | $175.7M |
| Q4 25 | — | $11.8M | ||
| Q3 25 | $119.2M | $2.8M | ||
| Q2 25 | — | $-19.4M | ||
| Q1 25 | — | $-21.4M | ||
| Q4 24 | — | $-8.8M | ||
| Q3 24 | $-51.8M | $-17.0M | ||
| Q2 24 | $-52.8M | $-17.5M | ||
| Q1 24 | $-39.6M | $-11.7M |
| Q4 25 | — | 80.7% | ||
| Q3 25 | — | 79.3% | ||
| Q2 25 | — | 77.0% | ||
| Q1 25 | — | 76.6% | ||
| Q4 24 | — | 77.1% | ||
| Q3 24 | — | 76.5% | ||
| Q2 24 | — | 76.8% | ||
| Q1 24 | — | 76.4% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | 52.2% | -1.5% | ||
| Q2 25 | — | -10.3% | ||
| Q1 25 | — | -12.0% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | — | -11.7% | ||
| Q2 24 | — | -13.0% | ||
| Q1 24 | — | -10.4% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | 57.4% | 1.2% | ||
| Q2 25 | — | -9.0% | ||
| Q1 25 | — | -10.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | -9.2% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | -6.7% |
| Q4 25 | — | $0.21 | ||
| Q3 25 | $1.33 | $0.05 | ||
| Q2 25 | — | $-0.35 | ||
| Q1 25 | — | $-0.38 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | $-0.60 | $-0.31 | ||
| Q2 24 | $-0.68 | $-0.32 | ||
| Q1 24 | $-0.53 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $338.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $-5.4M |
| Total Assets | $1.2B | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $338.8M | ||
| Q3 25 | $786.9M | $315.9M | ||
| Q2 25 | — | $284.3M | ||
| Q1 25 | — | $242.0M | ||
| Q4 24 | — | $301.8M | ||
| Q3 24 | $920.0M | $248.2M | ||
| Q2 24 | $701.7M | $267.9M | ||
| Q1 24 | $698.8M | $296.1M |
| Q4 25 | — | $-5.4M | ||
| Q3 25 | $1.1B | $-36.9M | ||
| Q2 25 | — | $-66.5M | ||
| Q1 25 | — | $-75.7M | ||
| Q4 24 | — | $-41.7M | ||
| Q3 24 | $1.2B | $-50.8M | ||
| Q2 24 | $931.7M | $-77.7M | ||
| Q1 24 | $935.3M | $-83.2M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | $973.7M | $1.2B | ||
| Q1 24 | $961.5M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $51.0M |
| Free Cash FlowOCF − Capex | $142.2M | $50.7M |
| FCF MarginFCF / Revenue | 68.4% | 21.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.19× | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $138.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $51.0M | ||
| Q3 25 | $142.2M | $46.2M | ||
| Q2 25 | — | $50.3M | ||
| Q1 25 | — | $-7.4M | ||
| Q4 24 | — | $44.0M | ||
| Q3 24 | $-49.2M | $18.9M | ||
| Q2 24 | $-32.9M | $-14.0K | ||
| Q1 24 | $-43.8M | $24.8M |
| Q4 25 | — | $50.7M | ||
| Q3 25 | $142.2M | $46.1M | ||
| Q2 25 | — | $49.3M | ||
| Q1 25 | — | $-8.1M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | $-49.7M | $18.7M | ||
| Q2 24 | $-33.9M | $-122.0K | ||
| Q1 24 | $-45.1M | $24.6M |
| Q4 25 | — | 21.2% | ||
| Q3 25 | 68.4% | 20.5% | ||
| Q2 25 | — | 22.9% | ||
| Q1 25 | — | -3.9% | ||
| Q4 24 | — | 21.6% | ||
| Q3 24 | — | 10.1% | ||
| Q2 24 | — | -0.1% | ||
| Q1 24 | — | 14.0% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | 4.31× | ||
| Q3 25 | 1.19× | 16.57× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDYA
Segment breakdown not available.
WK
| License And Service | $219.3M | 92% |
| XBRL Professional Services | $16.4M | 7% |
| Other Services | $3.2M | 1% |
